Assessment of Preclinical Target Organ Damage in Hypertension

Assessment of Preclinical Target Organ Damage in Hypertension

 In the natural history of hypertension, the compensatory increase in left ventricular mass ceases to be beneficial. Left ventricular hypertrophy (LVH) becomes a preclinical disease and an independent risk factor for congestive heart failure, ischemic heart disease, arrhythmia, sudden death, and stroke. In addition to elevated BP, several mechanisms are involved, including body size, age, gender, race, fibrogenic cytokines, and neurohumoral factors, notably angiotensin II, which favor interstitial collagen deposition and perivascular fibrosis. These tissue changes are responsible for the insidious contractile dysfunction that is associated with LVH, consequent to decreased coronary reserve and altered diastolic ventricular filling and relaxation. The cardinal investigations are echocardiography and electrocardiography. All antihypertensive drugs regress LVH, notably those that act on the renin-angiotensin-aldosterone system, which also could target the detrimental tissue changes. Regression enhances systolic midwall performance, normalizes autonomic function, and restores coronary reserve.

    Related Conference of Assessment of Preclinical Target Organ Damage in Hypertension

    May 30-31, 2024

    6th Euro Cardiology Congress

    Vienna, Austria
    May 30-31, 2024

    39th World Congress on Heart Diseases

    Vienna, Austria
    June 20-21, 2024

    5th European Summit on Cardiology Research

    Dublin, Ireland
    July 16-17, 2024

    13th World Heart Congress

    Paris, France
    August 01-02, 2024

    38th World Congress on Heart Diseases

    Montreal, Canada
    September 16-17, 2024

    3rd Global Summit on Cardiology and Cardiac Surgery

    Paris, France
    October 24-25, 2024

    11th International Conference on Interventional Cardiology

    Zurich, Switzerland
    October 30-31, 2024

    7th Global Cardiovascular Research and Clinical Cardiology

    Vancouver, Canada

    Assessment of Preclinical Target Organ Damage in Hypertension Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in